My watch list  


Systematic (IUPAC) name
1-[[(3R,5S)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid
CAS number 189059-71-0
ATC code  ?
PubChem  ?
Chemical data
Formula C31H39ClN2O8 
Mol. mass 603.103 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Lapaquistat (TAK-475) is a cholesterol-lowering drug currently in phase 3 clinical trials. Unlike statins which inhibit HMG-CoA reductase, lapaquistat metabolits inhibit squalene synthase which is further downstream in the synthesis of cholesterol. It is hoped that side effects can be reduced by not disturbing the mevalonate pathway which is important for other biochemical molecules besides cholesterol.


  • Davidson MH (Jan 2007). "Squalene synthase inhibition: a novel target for the management of dyslipidemia". Curr Atheroscler Rep 9 (1): 78-80. PMID 17169251.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lapaquistat". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE